SABCS Highlights: Advances in Oral SERD's for Breast Cancer
Dana-Farber
March 17, 2026
Harold Burstein, MD, PhD, and Rinath M. Jeselsohn, MD, discuss the lidERA, evERA, and EMBER-3 trials researching oral selective estrogen receptor degraders (SERDs).